Trials / Unknown
UnknownNCT02509806
Apatinib as Maintenance Therapy After First-line Chemotherapy(DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric Cancer
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Hebei Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of apatinib as maintenance therapy after first-line chemotherapy in Postoperative Recurrence / Metastasis Progressive Gastric Cancer.
Detailed description
Eligible patients will receive apatinib treatment(500mg qd p.o. q28d) until until disease progression or intolerable toxicity or patients withdrawal of consent after 4 cycles of DC first-line chemotherapy or only DC first-line chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | Apatinib Mesylate Tablets 500 mg qd p.o. |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2017-12-01
- Completion
- 2017-12-01
- First posted
- 2015-07-28
- Last updated
- 2017-10-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02509806. Inclusion in this directory is not an endorsement.